RLT
0.75
134.4%
88E
0.001
-50%
H2G
0.006
100%
NRZ
0.001
-50%
WOA
0.029
61.1%
TOU
0.008
-46.7%
PR2
0.079
33.9%
ALM
0.003
-40%
CTN
0.004
33.3%
CKA
0.036
-40%
BEZ
0.037
32.1%
ANR
0.007
-36.4%
STN
0.255
27.5%
DTM
0.004
-33.3%
SHO
0.028
27.3%
ECT
0.002
-33.3%
MLX
0.665
26.7%
NTM
0.002
-33.3%
AGR
0.049
25.6%
PUA
0.007
-30%
SMX
0.049
25.6%
OVT
0.005
-28.6%
AZY
0.47
25.3%
ID8
0.008
-27.3%
ADG
0.005
25%
CYB
0.073
-27%
LEG
0.01
25%
SLH
1.54
-22.2%
NMG
0.015
25%
OEC
0.09
-21.7%
VMC
0.12
25%
SNX
0.018
-21.7%
WSR
0.01
25%
RML
0.011
-21.4%
RWL
0.28
24.4%
RMS
2.2
-21.1%
EGR
0.155
24%
BSX
0.057
-20.8%
PSC
0.105
23.5%
CUE
0.1
-20%

Short Video: Tryptamine Therapeutics (ASX:TYP): Clinical-stage biotech focused on psychedelic drug development

Tryptamine Therapeutics Limited (ASX:TYP) is a clinical-stage biotech and its current primary focus is the development of an innovative and scalable intravenous-infused psilocin formulation which can be used in conjunction with psychotherapy to address significant unmet medical needs. Tryptamine Therapeutics CEO and Executive Director Jason Carroll speaks with The Stock Network’s Lel Smits.

🧬 Phase 2a clinical trial now underway – investigating the treatment of Irritable Bowel Syndrome, or IBS
🏥 Recently dosed the first patient at Massachusetts General Hospital, U.S.A
🍄 First time this prestigious hospital has administered psilocybin in a clinical setting

Watch the full interview ⚡ https://youtu.be/iug95UNKcMs